| pubmed-article:16416005 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16416005 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:16416005 | lifeskim:mentions | umls-concept:C0242640 | lld:lifeskim |
| pubmed-article:16416005 | lifeskim:mentions | umls-concept:C1136031 | lld:lifeskim |
| pubmed-article:16416005 | lifeskim:mentions | umls-concept:C1421319 | lld:lifeskim |
| pubmed-article:16416005 | lifeskim:mentions | umls-concept:C1555029 | lld:lifeskim |
| pubmed-article:16416005 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:16416005 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16416005 | pubmed:dateCreated | 2006-1-17 | lld:pubmed |
| pubmed-article:16416005 | pubmed:abstractText | Glucosylceramide synthase (GCS), the enzyme that converts ceramide to glucosylceramide, induce multidrug resistance (MDR) in cancer cells. Recently, RNA interference (RNAi) is a powerful strategy for gene therapy by introducing double-stranded RNA and leading to the sequence-specific destruction. We have designed two different short hairpin RNAs (shRNAs) targeting GCS and introduced them into adriamycin- resistant human breast cancer cells (MCF-7/AdrR cells) to inhibit GCS expression. The results demonstrated that the shRNAs targeting GCS decreased GCS mRNA, abolished GCS protein levels and restored the sensitivity of MCF-7/AdrR cells to several antineoplastic drugs. This study revealed that this approach can reverse MDR effectively and it may be applicable to cancer patients as a specific means to restore the sensitivity to chemotherapy. | lld:pubmed |
| pubmed-article:16416005 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16416005 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16416005 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16416005 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16416005 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16416005 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16416005 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16416005 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16416005 | pubmed:issn | 0028-2685 | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:GaiJJ | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:LimT PTP | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:WenD ZDZ | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:ZhangX-FXF | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:ZhangQ-HQH | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:ZhouG-YGY | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:LiK-NKN | lld:pubmed |
| pubmed-article:16416005 | pubmed:author | pubmed-author:ZhenJ-HJH | lld:pubmed |
| pubmed-article:16416005 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16416005 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:16416005 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16416005 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16416005 | pubmed:pagination | 1-8 | lld:pubmed |
| pubmed-article:16416005 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:meshHeading | pubmed-meshheading:16416005... | lld:pubmed |
| pubmed-article:16416005 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16416005 | pubmed:articleTitle | Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. | lld:pubmed |
| pubmed-article:16416005 | pubmed:affiliation | Department of Pathology, School of Medicine, Shandong University, 250012 Jinan, China. yanlinsunny@yahoo.com.cn | lld:pubmed |
| pubmed-article:16416005 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16416005 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16416005 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16416005 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16416005 | lld:pubmed |
